• 1251 Citations
  • 14 h-Index
1989 …2018
If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Magda Marcatti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 13 Similar Profiles
Multiple Myeloma Medicine & Life Sciences
Graft vs Host Disease Medicine & Life Sciences
Hematopoietic Stem Cell Transplantation Medicine & Life Sciences
treosulfan Medicine & Life Sciences
Cyclophosphamide Medicine & Life Sciences
Thalidomide Medicine & Life Sciences
Transplantation Medicine & Life Sciences
Mortality Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1989 2018

  • 1251 Citations
  • 14 h-Index
  • 44 Article
  • 4 Review article

Clinical Impact of Pretransplant Multidrug-Resistant Gram-Negative Colonization in Autologous and Allogeneic Hematopoietic Stem Cell Transplantation

Forcina, A., Lorentino, F., Marasco, V., Oltolini, C., Marcatti, M., Greco, R., Lupo-Stanghellini, MT., Carrabba, M., Bernardi, M., Peccatori, J., Corti, C. & Ciceri, F., 2018, In : Biology of Blood and Marrow Transplantation. 24, 7, p. 1476-1482 7 p.

Research output: Contribution to journalArticle

Hematopoietic Stem Cell Transplantation
Gram-Negative Bacteria
Mortality
Transplants
Survival

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., Guglielmelli, T., Baldini, L., Gamberi, B., Rizzi, R., De Sabbata, G., Di Renzo, N., Patriarca, F., Pezzatti, S., Siniscalchi, A., Ribolla, R. & 5 others, Palumbo, A., Montefusco, V., Nagler, A., Boccadoro, M. & Gay, F., Dec 2018, In : Critical Reviews in Oncology/Hematology. 132, p. 9-16 8 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Therapeutics
Proteasome Inhibitors
Survival
Immunologic Factors
1 Citation (Scopus)

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., Guglielmelli, T., Baldini, L., Gamberi, B., Rizzi, R., De Sabbata, G., Di Renzo, N., Patriarca, F., Pezzatti, S., Siniscalchi, A., Ribolla, R. & 5 others, Palumbo, A., Montefusco, V., Nagler, A., Boccadoro, M. & Gay, F., Dec 1 2018, In : Critical Reviews in Oncology/Hematology. 132, p. 9-16 8 p.

Research output: Contribution to journalReview article

Multiple Myeloma
Therapeutics
Proteasome Inhibitors
Survival
Immunologic Factors

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, M. T., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., Guglielmelli, T., Baldini, L., Gamberi, B., Rizzi, R., De Sabbata, G., Di Renzo, N., Patriarca, F., Pezzatti, S., Siniscalchi, A., Ribolla, R. & 5 others, Palumbo, A., Montefusco, V., Nagler, A., Boccadoro, M. & Gay, F., 2018, In : Critical Reviews in Oncology/Hematology. 132, p. 9-16 8 p.

Research output: Contribution to journalArticle

Continuous therapy in standard- and high-risk newly-diagnosed multiple myeloma: A pooled analysis of 2 phase III trials

D'Agostino, M., De Paoli, L., Conticello, C., Offidani, M., Ria, R., Petrucci, MT., Spada, S., Marcatti, M., Catalano, L., Gilestro, M., Guglielmelli, T., Baldini, L., Gamberi, B., Rizzi, R., De Sabbata, G., Di Renzo, N., Patriarca, F., Pezzatti, S., Siniscalchi, A., Ribolla, R. & 5 others, Palumbo, A., Montefusco, V., Nagler, A., Boccadoro, M. & Gay, F., 2018, In : Critical Reviews in Oncology/Hematology. 132, p. 9-16 8 p.

Research output: Contribution to journalArticle

Multiple Myeloma
Therapeutics
Proteasome Inhibitors
Survival
Immunologic Factors